Danaher Corporation $DHR Shares Purchased by Value Partners Investments Inc.

Key Points

• Value Partners Investments Inc. increased its stake in Danaher Corporation by 57.2%, bringing its position to 4,297 shares valued at approximately $848,000.
• Danaher reported quarterly earnings of $1.80 per share, exceeding analyst expectations by $0.16, with revenue up 3.4% year-over-year at $5.94 billion.
• The company announced a quarterly dividend of $0.32 per share, with an ex-dividend date of September 26th, reflecting an annualized yield of 0.7%.

Value Partners Investments Inc. boosted its stake in Danaher Corporation (NYSE:DHR - Free Report) by 57.2% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 4,297 shares of the conglomerate's stock after purchasing an additional 1,563 shares during the period. Value Partners Investments Inc.'s holdings in Danaher were worth $848,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of DHR. GHP Investment Advisors Inc. boosted its stake in shares of Danaher by 396.0% in the first quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate's stock valued at $25,000 after purchasing an additional 99 shares during the period. Heck Capital Advisors LLC purchased a new stake in shares of Danaher during the fourth quarter worth $27,000. Sierra Ocean LLC raised its stake in shares of Danaher by 116.9% in the first quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate's stock valued at $29,000 after acquiring an additional 76 shares in the last quarter. Smallwood Wealth Investment Management LLC purchased a new position in Danaher in the first quarter valued at $31,000. Finally, Dunhill Financial LLC raised its position in Danaher by 68.4% in the 1st quarter. Dunhill Financial LLC now owns 165 shares of the conglomerate's stock valued at $34,000 after purchasing an additional 67 shares in the last quarter. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Price Performance

DHR stock traded up $1.89 during trading on Tuesday, reaching $190.43. 4,817,643 shares of the company were exchanged, compared to its average volume of 3,203,970. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.22 and a current ratio of 1.62. The stock's 50 day moving average price is $200.77 and its 200 day moving average price is $198.59. Danaher Corporation has a 52-week low of $171.00 and a 52-week high of $279.90. The company has a market cap of $136.36 billion, a P/E ratio of 40.52, a PEG ratio of 2.63 and a beta of 0.75.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, topping analysts' consensus estimates of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The business had revenue of $5.94 billion for the quarter, compared to analysts' expectations of $5.83 billion. During the same quarter in the prior year, the firm posted $1.72 EPS. The company's revenue was up 3.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, analysts predict that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be given a $0.32 dividend. The ex-dividend date is Friday, September 26th. This represents a $1.28 annualized dividend and a dividend yield of 0.7%. Danaher's dividend payout ratio is currently 27.23%.

Analyst Ratings Changes

A number of research firms have recently commented on DHR. Guggenheim reiterated a "buy" rating and issued a $250.00 price objective on shares of Danaher in a report on Wednesday, July 23rd. UBS Group decreased their price objective on Danaher from $240.00 to $225.00 and set a "buy" rating for the company in a report on Wednesday, July 23rd. Wells Fargo & Company lowered their price objective on shares of Danaher from $210.00 to $205.00 and set an "equal weight" rating on the stock in a research report on Wednesday, July 23rd. Scotiabank raised Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 price objective for the company in a research note on Friday, July 11th. Finally, Evercore ISI decreased their price target on Danaher from $230.00 to $226.00 and set an "outperform" rating for the company in a report on Tuesday, July 8th. Seventeen analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. According to MarketBeat.com, Danaher currently has a consensus rating of "Moderate Buy" and an average target price of $246.35.

Insider Buying and Selling at Danaher

In related news, Director Teri List sold 2,778 shares of Danaher stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the transaction, the director directly owned 20,751 shares in the company, valued at $4,379,706.06. The trade was a 11.81% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 11.20% of the stock is currently owned by company insiders.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.